Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 3: Second/subsequential Treatment Decision-making
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
16 Tammi 202416min
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 4: Novel Drugs in Development
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
16 Tammi 202424min
Expert Interview: Frequently Asked Questions (FAQs) for Non Muscle Invasive Bladder Cancer (NMIBC)
About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose in...
3 Marras 20237min
Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a spe...
3 Marras 202313min
Expert Interview: Frequently Asked Questions (FAQs) for Second Line (2L) and Salvage Treatments
There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. I...
3 Marras 202310min
Expert Interview: Frequently Asked Questions (FAQs) for First Line (1L) Treatment Decision making
Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving...
3 Marras 202317min
Current standard of care for ES SCLC
In this first of three podcasts on extensive-stage SCLC, the experts discuss the management of patients with relapsed SCLC based on current evidence and guidelines.
14 Joulu 202216min
Closer look at the biology of SCLC and molecular subtypes
In the second podcast on extensive-stage SCLC, the experts examine the biology of SCLC and discuss the molecular subtypes, which have distinct therapeutic vulnerabilities.
14 Joulu 202210min
